SCHEMBL4486035

SCHEMBL4486035

CC(C)S(=O)(=O)N(CCN(C)C)c1ccc(N/C(=C2\C(=O)Nc3cc(F)ccc32)c2ccccc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.36
FLT3 P36888 2/20 0.35
PDGFRB P09619 2/20 0.34
BRD4 O60885 2/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
HTT P42858 2/20 0.32
POLB P06746 1/20 0.32
CASP3 P42574 1/20 0.32
MAPT P10636 4/20 0.31
TP53 P04637 2/20 0.31
AURKA O14965 1/20 0.31
PDGFRA P16234 1/20 0.31
KDR P35968 1/20 0.31
AURKB Q96GD4 1/20 0.31
AURKC Q9UQB9 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
NCOA3 Q9Y6Q9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4486037 1.00 BACE1 (0.36) BACE1FLT3PDGFRBBRD4MEN1
SCHEMBL4484962 0.91 BACE1 (0.38) BACE1FLT3PDGFRBBRD4MEN1
SCHEMBL4484967 0.91 BACE1 (0.38) BACE1FLT3PDGFRBBRD4MEN1
SCHEMBL4490963 0.90 GPR27 (0.33) MEN1KMT2ACASP3MAPTTP53
SCHEMBL4490965 0.90 GPR27 (0.33) MEN1KMT2ACASP3MAPTTP53
SCHEMBL4480738 0.90 BACE1 (0.38) BACE1FLT3PDGFRBBRD4MEN1
SCHEMBL4480741 0.90 BACE1 (0.38) BACE1FLT3PDGFRBBRD4MEN1
SCHEMBL6318984 0.90 MEN1 (0.34) BRD4MEN1KMT2APOLBMAPT
SCHEMBL6318980 0.90 MEN1 (0.34) BRD4MEN1KMT2APOLBMAPT
SCHEMBL4485545 0.89 RORC (0.37) BACE1FLT3PDGFRBBRD4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR BACE1 1615/4885FLT3 34/4885PDGFRB 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.